---
document_datetime: 2025-12-29 08:31:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/upstaza.html
document_name: upstaza.html
version: success
processing_time: 0.107499
conversion_datetime: 2025-12-30 21:51:29.114107
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Upstaza

[RSS](/en/individual-human-medicine.xml/67574)

##### Authorised

This medicine is authorised for use in the European Union

eladocagene exuparvovec Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Upstaza](#news-on)
- [More information on Upstaza](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Upstaza is a gene therapy medicine that is used in adults and children aged 18 months and older with severe aromatic L-amino acid decarboxylase (AADC) deficiency with a genetically confirmed diagnosis.

AADC deficiency is an inherited disease that affects the nervous system leading to symptoms such as developmental delays, weak muscle tone and inability to control the movement of the limbs.

AADC deficiency is rare, and Upstaza was designated an 'orphan medicine' (a medicine used in rare diseases) on 18 November 2016. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3161786](/en/medicines/human/orphan-designations/eu-3-16-1786) .

Upstaza is a type of advanced therapy medicine called a 'gene therapy product'. This is a type of medicine that works by delivering genes into the body.

Upstaza contains eladocagene exuparvovec, a functional version of the AADC gene within a modified virus (adeno-associated viral vector). The virus used in this medicine is not known to cause a disease in humans.

Expand section

Collapse section

## How is Upstaza used?

Upstaza can only be obtained with a prescription and must be given in an operating room under anaesthetic by a doctor who is experienced in brain surgery. It is given by infusion into the brain. After infusion the patient has a brain scan. The doctor will monitor recovery and check for any side effects from the surgery and treatment.

For more information about using Upstaza, see the package leaflet or contact your doctor or pharmacist.

## How does Upstaza work?

AADC deficiency is caused by mutations in the gene that produces the AADC enzyme. This enzyme is needed to produce dopamine, a neurotransmitter that is important for controlling movement. Patients with AADC deficiency do not have a properly working version of the enzyme, resulting in very little or no dopamine production in the brain. The medicine consists of a virus that contains a working version of the AADC gene. When given to the patient, it is expected that the virus will carry the AADC gene into nerve cells, enabling them to produce the missing enzyme. This in turn is expected to enable the cells to produce the dopamine they need to work properly, thus improving symptoms of the condition.

## What benefits of Upstaza have been shown in studies?

Benefits of Upstaza were shown in three main studies involving 28 children aged 1.5 to 8.5 years with severe AADC deficiency confirmed by a genetic test. The main measures of effectiveness were head control and the ability to sit unassisted. The studies showed that around 70% (14 out of 20) of patients were able to control head movement and around 65% (12 out of 20) of patients could sit unassisted two years after treatment. Data from scientific literature showed that patients with severe AADC deficiency who had not received any treatment could not achieve these developmental milestones.

## What are the risks associated with Upstaza?

The most common side effect with Upstaza (which may affect more than 1 in 10 people) is dyskinesia (uncontrollable movements).

For the full list of side effects and restrictions with Upstaza, see the package leaflet.

## Why is Upstaza authorised in the EU?

Three main studies have shown that Upstaza is effective at improving the ability to control head movement and to sit in patients with AADC deficiency. Because AADC deficiency is a very rare disease, the study was small but the short-term data available indicated that Upstaza could be effective at achieving important developmental milestones in children. Although the data on the safety of Upstaza are limited, the side effects seen to date are considered manageable. The European Medicines Agency decided that Upstaza's benefits are greater than its risks and it can be authorised for use in the EU, also in adults with AADC deficiency, given the seriousness of the condition and the lack of existing treatments.

Upstaza has been authorised under 'exceptional circumstances'. This means that, because the indication is encountered so rarely, it has not been possible to obtain full information about the medicine. Every year, the European Medicines Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Upstaza?

Since Upstaza has been authorised under exceptional circumstances, the company that markets Upstaza will provide additional data from ongoing studies and carry out a new study to further characterise the long-term safety and effectiveness of Upstaza.

## What measures are being taken to ensure the safe and effective use of Upstaza?

The company that markets Upstaza must ensure that hospitals where Upstaza is given have appropriate expertise, facilities and training.

The company must provide educational materials for healthcare professionals and patients about the surgical procedure and possible side effects.

The company must also provide additional data to further show that Upstaza is consistently manufactured with the same quality standards.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Upstaza have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Upstaza are continuously monitored. Suspected side effects reported with Upstaza are carefully evaluated and any necessary action taken to protect patients.

## Other information about Upstaza

Upstaza received a marketing authorisation valid throughout the EU on 18 July 2022.

Upstaza : EPAR - Medicine overview

Reference Number: EMEA/H/C/005352

English (EN) (102.94 KB - PDF)

**First published:** 09/08/2022

[View](/en/documents/overview/upstaza-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-951)

български (BG) (154.64 KB - PDF)

**First published:**

09/08/2022

[View](/bg/documents/overview/upstaza-epar-medicine-overview_bg.pdf)

español (ES) (102.14 KB - PDF)

**First published:**

09/08/2022

[View](/es/documents/overview/upstaza-epar-medicine-overview_es.pdf)

čeština (CS) (125.34 KB - PDF)

**First published:**

09/08/2022

[View](/cs/documents/overview/upstaza-epar-medicine-overview_cs.pdf)

dansk (DA) (102.74 KB - PDF)

**First published:**

09/08/2022

[View](/da/documents/overview/upstaza-epar-medicine-overview_da.pdf)

Deutsch (DE) (106.63 KB - PDF)

**First published:**

09/08/2022

[View](/de/documents/overview/upstaza-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.74 KB - PDF)

**First published:**

09/08/2022

[View](/et/documents/overview/upstaza-epar-medicine-overview_et.pdf)

ελληνικά (EL) (129.19 KB - PDF)

**First published:**

09/08/2022

[View](/el/documents/overview/upstaza-epar-medicine-overview_el.pdf)

français (FR) (104.06 KB - PDF)

**First published:**

09/08/2022

[View](/fr/documents/overview/upstaza-epar-medicine-overview_fr.pdf)

hrvatski (HR) (123.8 KB - PDF)

**First published:**

09/08/2022

[View](/hr/documents/overview/upstaza-epar-medicine-overview_hr.pdf)

italiano (IT) (102.15 KB - PDF)

**First published:**

09/08/2022

[View](/it/documents/overview/upstaza-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (139.84 KB - PDF)

**First published:**

09/08/2022

[View](/lv/documents/overview/upstaza-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (135.28 KB - PDF)

**First published:**

09/08/2022

[View](/lt/documents/overview/upstaza-epar-medicine-overview_lt.pdf)

magyar (HU) (124.67 KB - PDF)

**First published:**

09/08/2022

[View](/hu/documents/overview/upstaza-epar-medicine-overview_hu.pdf)

Malti (MT) (135.62 KB - PDF)

**First published:**

09/08/2022

[View](/mt/documents/overview/upstaza-epar-medicine-overview_mt.pdf)

Nederlands (NL) (103.45 KB - PDF)

**First published:**

09/08/2022

[View](/nl/documents/overview/upstaza-epar-medicine-overview_nl.pdf)

polski (PL) (127.83 KB - PDF)

**First published:**

09/08/2022

[View](/pl/documents/overview/upstaza-epar-medicine-overview_pl.pdf)

português (PT) (102.88 KB - PDF)

**First published:**

09/08/2022

[View](/pt/documents/overview/upstaza-epar-medicine-overview_pt.pdf)

română (RO) (121.17 KB - PDF)

**First published:**

09/08/2022

[View](/ro/documents/overview/upstaza-epar-medicine-overview_ro.pdf)

slovenčina (SK) (125.47 KB - PDF)

**First published:**

09/08/2022

[View](/sk/documents/overview/upstaza-epar-medicine-overview_sk.pdf)

slovenščina (SL) (123.76 KB - PDF)

**First published:**

09/08/2022

[View](/sl/documents/overview/upstaza-epar-medicine-overview_sl.pdf)

Suomi (FI) (99.78 KB - PDF)

**First published:**

09/08/2022

[View](/fi/documents/overview/upstaza-epar-medicine-overview_fi.pdf)

svenska (SV) (100.3 KB - PDF)

**First published:**

09/08/2022

[View](/sv/documents/overview/upstaza-epar-medicine-overview_sv.pdf)

Upstaza : EPAR - Risk management plan summary

English (EN) (172.29 KB - PDF)

**First published:** 09/08/2022

[View](/en/documents/rmp-summary/upstaza-epar-risk-management-plan-summary_en.pdf)

## Product information

Upstaza : EPAR - Product Information

English (EN) (582.11 KB - PDF)

**First published:** 09/08/2022

**Last updated:** 02/12/2025

[View](/en/documents/product-information/upstaza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-10)

български (BG) (733.36 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/bg/documents/product-information/upstaza-epar-product-information_bg.pdf)

español (ES) (670.3 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/es/documents/product-information/upstaza-epar-product-information_es.pdf)

čeština (CS) (956.76 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/cs/documents/product-information/upstaza-epar-product-information_cs.pdf)

dansk (DA) (627.81 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/da/documents/product-information/upstaza-epar-product-information_da.pdf)

Deutsch (DE) (686.09 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/de/documents/product-information/upstaza-epar-product-information_de.pdf)

eesti keel (ET) (622.75 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/et/documents/product-information/upstaza-epar-product-information_et.pdf)

ελληνικά (EL) (668.57 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/el/documents/product-information/upstaza-epar-product-information_el.pdf)

français (FR) (643.5 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/fr/documents/product-information/upstaza-epar-product-information_fr.pdf)

hrvatski (HR) (641.95 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/hr/documents/product-information/upstaza-epar-product-information_hr.pdf)

íslenska (IS) (622.52 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/is/documents/product-information/upstaza-epar-product-information_is.pdf)

italiano (IT) (628.08 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/it/documents/product-information/upstaza-epar-product-information_it.pdf)

latviešu valoda (LV) (659.36 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/lv/documents/product-information/upstaza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (671.34 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/lt/documents/product-information/upstaza-epar-product-information_lt.pdf)

magyar (HU) (785.01 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/hu/documents/product-information/upstaza-epar-product-information_hu.pdf)

Malti (MT) (678.03 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/mt/documents/product-information/upstaza-epar-product-information_mt.pdf)

Nederlands (NL) (626.64 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/nl/documents/product-information/upstaza-epar-product-information_nl.pdf)

norsk (NO) (597.9 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/no/documents/product-information/upstaza-epar-product-information_no.pdf)

polski (PL) (714.8 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/pl/documents/product-information/upstaza-epar-product-information_pl.pdf)

português (PT) (626.09 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/pt/documents/product-information/upstaza-epar-product-information_pt.pdf)

română (RO) (637.15 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/ro/documents/product-information/upstaza-epar-product-information_ro.pdf)

slovenčina (SK) (655.01 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/sk/documents/product-information/upstaza-epar-product-information_sk.pdf)

slovenščina (SL) (632.66 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/sl/documents/product-information/upstaza-epar-product-information_sl.pdf)

Suomi (FI) (662.03 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/fi/documents/product-information/upstaza-epar-product-information_fi.pdf)

svenska (SV) (633.31 KB - PDF)

**First published:**

09/08/2022

**Last updated:**

02/12/2025

[View](/sv/documents/product-information/upstaza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000312499 02/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Upstaza : EPAR - All Authorised Presentations

English (EN) (42.51 KB - PDF)

**First published:** 09/08/2022

[View](/en/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-84)

български (BG) (50.67 KB - PDF)

**First published:**

09/08/2022

[View](/bg/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.43 KB - PDF)

**First published:**

09/08/2022

[View](/es/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (50.97 KB - PDF)

**First published:**

09/08/2022

[View](/cs/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (43.35 KB - PDF)

**First published:**

09/08/2022

[View](/da/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (44.28 KB - PDF)

**First published:**

09/08/2022

[View](/de/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.21 KB - PDF)

**First published:**

09/08/2022

[View](/et/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.59 KB - PDF)

**First published:**

09/08/2022

[View](/el/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_el.pdf)

français (FR) (42.48 KB - PDF)

**First published:**

09/08/2022

[View](/fr/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (58.52 KB - PDF)

**First published:**

09/08/2022

[View](/hr/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (42.82 KB - PDF)

**First published:**

09/08/2022

[View](/is/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_is.pdf)

italiano (IT) (41.64 KB - PDF)

**First published:**

09/08/2022

[View](/it/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (44.52 KB - PDF)

**First published:**

09/08/2022

[View](/lv/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.36 KB - PDF)

**First published:**

09/08/2022

[View](/lt/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (51.49 KB - PDF)

**First published:**

09/08/2022

[View](/hu/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (60.79 KB - PDF)

**First published:**

09/08/2022

[View](/mt/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (42.05 KB - PDF)

**First published:**

09/08/2022

[View](/nl/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (43.25 KB - PDF)

**First published:**

09/08/2022

[View](/no/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.43 KB - PDF)

**First published:**

09/08/2022

[View](/pl/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_pl.pdf)

português (PT) (43.86 KB - PDF)

**First published:**

09/08/2022

[View](/pt/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.66 KB - PDF)

**First published:**

09/08/2022

[View](/ro/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.4 KB - PDF)

**First published:**

09/08/2022

[View](/sk/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (49.69 KB - PDF)

**First published:**

09/08/2022

[View](/sl/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (41.67 KB - PDF)

**First published:**

09/08/2022

[View](/fi/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (42.39 KB - PDF)

**First published:**

09/08/2022

[View](/sv/documents/all-authorised-presentations/upstaza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Upstaza Active substance Eladocagene exuparvovec International non-proprietary name (INN) or common name eladocagene exuparvovec Therapeutic area (MeSH) Amino Acid Metabolism, Inborn Errors Anatomical therapeutic chemical (ATC) code A16AB26

### Pharmacotherapeutic group

- Other alimentary tract and metabolism products
- Enzymes

### Therapeutic indication

Upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L amino acid decarboxylase (AADC) deficiency with a severe phenotype (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005352

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

PTC Therapeutics International Limited

70 Sir John Rogerson's Quay

Opinion adopted 19/05/2022 Marketing authorisation issued 18/07/2022 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Upstaza : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (151.97 KB - PDF)

**First published:** 02/12/2025

[View](/en/documents/procedural-steps-after/upstaza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Upstaza : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (172.33 KB - PDF)

**First published:** 20/09/2022

**Last updated:** 02/12/2025

[View](/en/documents/procedural-steps-after/upstaza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Upstaza : EPAR - Orphan Maintenance Assessment Report

Draft

Reference Number: EMA/OD/0000024196

English (EN) (397.51 KB - PDF)

**First published:** 10/08/2022

[View](/en/documents/orphan-maintenance-report-post/upstaza-epar-orphan-maintenance-assessment-report_en.pdf)

## Initial marketing authorisation documents

Upstaza : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/CHMP/571076/2022

English (EN) (3.53 MB - PDF)

**First published:** 09/08/2022

[View](/en/documents/assessment-report/upstaza-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Upstaza

Adopted

Reference Number: EMA/CHMP/274542/2022

English (EN) (157.99 KB - PDF)

**First published:** 20/05/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-upstaza_en.pdf)

#### News on Upstaza

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-may-2022) 20/05/2022

[First therapy to treat rare genetic nervous system disorder AADC deficiency](/en/news/first-therapy-treat-rare-genetic-nervous-system-disorder-aadc-deficiency) 20/05/2022

#### More information on Upstaza

- [EU/3/16/1786 - orphan designation for treatment of aromatic L-amino acid decarboxylase deficiency](/en/medicines/human/orphan-designations/eu-3-16-1786)
- [EMEA-002435-PIP01-18-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002435-pip01-18-m03)

**This page was last updated on** 02/12/2025

## Share this page

[Back to top](#main-content)